[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-detail-351637-en":59,"doc-seo-351637-105":100},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":5,"data":60},{"doc_id":61,"user_id":62,"nickname":63,"user_avatar":64,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":66,"doc_content":67,"file_id":68,"file_url":69,"file_type":70,"file_size":71,"view_count":72,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":73,"language":74,"language_code":75,"site_id":76,"html_lang":75,"table_of_contents":77,"faqs":78,"seo_title":79,"seo_description":66,"update_tm":80,"read_time":81,"preview_page_count":19,"preview_urls":82},351637,1374402968488,"Đào","https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","Basroparib inhibits YAP-driven cancers by stabilizing angiomotin","Basroparib is a selective tankyrase (TNKS) inhibitor that suppresses Wnt signaling and attenuates YAP-driven oncogenic programs by stabilizing angiomotin (AMOT), an endogenous negative regulator of YAP. In colorectal cancer cells, it increases AMOT protein abundance, promotes AMOT–YAP complex formation, and sequesters YAP in the cytoplasm to reduce YAP-dependent transcription. It preferentially sensitizes YAP-overexpressing KRAS-mutant CRC models to MEK inhibition. In MEK inhibitor–resistant systems, basroparib restores sensitivity in vitro and in vivo, including improved MEK efficacy across other YAP-active tumor types.","Basroparib inhibits YAP-driven cancers by stabilizing angiomotin  \nYoung-Ju Kwon 1,2, Dong Young Kim 1, Yuna Kim 1, Uk-Il Kim3 and Jae-Sung Kim 1,2   \n1 Division of Radiation Biomedical Research, Korea Institute of Radiological and Medical Sciences, Seoul, Korea  \n2 Radiological and Medico-Oncological Sciences, University of Science and Technology, Seoul, Korea  \n3 ST Pharm Co., Ltd., Seoul, Korea  \nKeywords  \nangiomotin; basroparib; MEK inhibitor resistance; tankyrase inhibitor; YAP  \nCorrespondence  \nJ.-S. Kim, Division of Radiation Biomedical Research, Korea Institute of Radiological and Medical Sciences, Nowon-ro 75, Nowon-gu, Seoul 01812, Korea  \nFax: +82 2 970 2417  \nTel: +82 2 970 1669  \nE-mail: [jaesung@kirams.re.kr](jaesung@kirams.re.kr)  \nYoung-Ju Kwon and Dong Young Kim contributed equally to this work  \n(Received 29 July 2025, revised 12  \nDecember 2025, accepted 12 January 2026, available online 22 January 2026)  \ndoi:10 . 1002/1878-0261 .70209  \nYes-associated protein (YAP) is a key oncogenic effector and a well-established driver of resistance to anticancer therapies, especially in tumors harboring KRAS mutations. Although YAP is clinically relevant, drug-development efforts that directly inhibit its activity have been limited. Here, we show that basroparib—a selective tankyrase (TNKS) inhibitor that suppresses Wnt signaling—attenuates YAP-driven oncogenic programs by stabilizing angiomotin (AMOT), an endogenous negative regulator of YAP. In colorectal cancer (CRC) cells, basroparib increased AMOT protein abundance, promoted AMOT–YAP complex formation, and enforced cytoplasmic sequestration of YAP, thereby dampening YAP-dependent transcription. Basroparib preferentially sensitized YAP-overexpressing, KRAS-mutant CRC cell lines to MEK inhibition by inhibiting YAP signaling. In MEK inhibitor-resistant CRC models, in which elevated YAP activity mediates escape, basroparib restored drug sensitivity both in vitro and in vivo. The compound also enhanced MEK inhibitor efﬁcacy in other YAP-active tumor types, while exerting minimal effects in YAP-inactive models. Taken together, these results identify basroparib—now progressing through clinical development (Phase I, NCT04505839)—as a promising agent for dual Wnt–YAP pathway blockade and for overcoming therapeutic resistance in YAP-driven cancers.  \n1. Introduction  \nYes-associated protein (YAP), a key transcriptional coactivator within the Hippo signaling pathway, plays a pivotal role in tumor progression and resistance to targeted therapies, including MEK inhibitors [1–3] . Asa core effector of the Hippo pathway, YAP is frequently upregulated in various cancers, where it  \npromotes oncogenesis by regulating genes involved in cell proliferation, apoptosis, and stemness [3] . Under physiological conditions, the Hippo pathway—comprising MST1/2, SAV1, LATS1/2, YAP, and its paralog TAZ—maintains tissue homeostasis by balancing cell growth and cell death. Dysregulation of this  \nAbbreviations  \nAMOT, angiomotin; Bas, basroparib; CHX, cycloheximide; CI, combination index; CRC, colorectal cancer; CTGF, connective tissue growth factor; CYR61, cysteine-rich angiogenic inducer 61; ERK, extracellular signal-regulated kinase; FBS, fetal bovine serum; KRAS, kirsten rat sarcoma; MEK, mitogen-activated protein kinase kinase; ns, not signiﬁcant; PO, Per OS (by mouth); PI3K, phosphoinositide 3-kinase; QD, Quaque die (daily); SAV1, salvador homolog 1; SCH, SCH772984; TAZ, transcriptional coactivator with PDZ-binding motif; TEAD4, transcriptional enhancer activator domain4; TGI, tumor growth inhibition; TNKS, tankyrase; Tra, trametinib; Veh, vehicle; WT, wild-type; YAP, yes-associated protein; CDK2/4/6, cyclin-dependent kinase2/4/6; AMOTL1/2, angiomotin like 1/2; LATS1/2, large tumor suppressor1/2; MST1/2, mammalian STE20-like protein kinase 1/2 .  \n1284 Molecular Oncology 20 (2026) 1284–1298 ª 2026 The Author(s) . Molecular Oncology published by John Wiley & Sons Ltd on behalf of  \nFeder","cbCaiuGssJmTNscO","https://ap.wps.com/l/cbCaiuGssJmTNscO","pdf",3559191,17,15,"English","en",105,"# Introduction\n## YAP and Hippo signaling in cancer\n## Wnt–YAP crosstalk and therapeutic resistance","[{\"question\":\"What is the main mechanism by which basroparib affects YAP activity?\",\"answer\":\"Basroparib stabilizes angiomotin (AMOT). This promotes AMOT–YAP complex formation and cytoplasmic sequestration of YAP, which dampens YAP-dependent transcription.\"},{\"question\":\"How does basroparib influence MEK inhibitor sensitivity in colorectal cancer?\",\"answer\":\"Basroparib preferentially sensitizes YAP-overexpressing, KRAS-mutant colorectal cancer cells to MEK inhibition. In MEK inhibitor–resistant models where elevated YAP mediates escape, it restores drug sensitivity both in vitro and in vivo.\"},{\"question\":\"Why is the Wnt–YAP pathway important for resistance to therapy?\",\"answer\":\"In colorectal cancer, YAP signaling is tightly integrated with the Wnt/b-catenin pathway. Wnt activation disrupts the β-catenin destruction complex, enabling nuclear β-catenin signaling, while nuclear YAP enhances TEAD-dependent gene expression and co-operates with β-catenin/TCF complexes to drive stemness and resistance.\"}]","Basroparib inhibits YAP-driven cancers by stabilizing angiomotin | PDF",1790095067,38,[83,87,91,96],{"page_no":8,"url":84,"width":85,"height":86},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0f221fccce69bf16aa01b8f60b893103.webp",983,1291,{"page_no":14,"url":88,"width":89,"height":90},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0c330717a698f4f53bd1ff02d8a5e287.webp",982,1290,{"page_no":92,"url":93,"width":94,"height":95},3,"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e001522dbc89509cb83e4308f20b2df0.webp",981,1289,{"page_no":19,"url":97,"width":98,"height":99},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9f7e20d26ca2ebe3ffdce6c49fc4bf68.webp",980,1287,{"code":4,"msg":101,"data":102},"ok",{"site_id":76,"language":75,"slug":103,"title":65,"keywords":104,"description":66,"schema_data":105,"social_meta":158,"head_meta":160,"extra_data":162,"updated_unix":163},"basroparib-inhibits-yap-driven-cancers-by-stabilizing-angiomotin","",{"@graph":106,"@context":157},[107,120,140],{"@type":108,"itemListElement":109},"BreadcrumbList",[110,114,116,118],{"item":111,"name":112,"@type":113,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":115,"name":9,"@type":113,"position":14},"https://docshare.wps.com/document/",{"item":117,"name":40,"@type":113,"position":92},"https://docshare.wps.com/document/research-report/",{"item":119,"name":65,"@type":113,"position":19},"https://docshare.wps.com/document/basroparib-inhibits-yap-driven-cancers-by-stabilizing-angiomotin/351637/",{"url":119,"name":65,"@type":121,"image":122,"author":127,"headline":65,"publisher":129,"fileFormat":132,"inLanguage":75,"description":66,"dateModified":133,"datePublished":134,"encodingFormat":132,"isAccessibleForFree":135,"interactionStatistic":136},"DigitalDocument",{"url":123,"@type":124,"width":125,"height":126},"https://docshare.wps.com/thumbnails/basroparib-inhibits-yap-driven-cancers-by-stabilizing-angiomotin/351637.png","ImageObject",300,407,{"name":63,"@type":128},"Person",{"url":111,"name":130,"@type":131},"DocShare","Organization","application/pdf","2026-11-18","2026-09-22",true,{"@type":137,"interactionType":138,"userInteractionCount":72},"InteractionCounter",{"@type":139},"ViewAction",{"@type":141,"mainEntity":142},"FAQPage",[143,149,153],{"name":144,"@type":145,"acceptedAnswer":146},"What is the main mechanism by which basroparib affects YAP activity?","Question",{"text":147,"@type":148},"Basroparib stabilizes angiomotin (AMOT). This promotes AMOT–YAP complex formation and cytoplasmic sequestration of YAP, which dampens YAP-dependent transcription.","Answer",{"name":150,"@type":145,"acceptedAnswer":151},"How does basroparib influence MEK inhibitor sensitivity in colorectal cancer?",{"text":152,"@type":148},"Basroparib preferentially sensitizes YAP-overexpressing, KRAS-mutant colorectal cancer cells to MEK inhibition. In MEK inhibitor–resistant models where elevated YAP mediates escape, it restores drug sensitivity both in vitro and in vivo.",{"name":154,"@type":145,"acceptedAnswer":155},"Why is the Wnt–YAP pathway important for resistance to therapy?",{"text":156,"@type":148},"In colorectal cancer, YAP signaling is tightly integrated with the Wnt/b-catenin pathway. Wnt activation disrupts the β-catenin destruction complex, enabling nuclear β-catenin signaling, while nuclear YAP enhances TEAD-dependent gene expression and co-operates with β-catenin/TCF complexes to drive stemness and resistance.","https://schema.org",{"og:url":119,"og:type":159,"og:title":65,"og:site_name":130,"og:description":66},"article",{"robots":161,"canonical":119},"index,follow",{"doc_id":61,"site_id":76},1790198516]